ECSP055814A - Composición farmacéutica a base de un agonista de receptor adrenérgico beta-3 y un inhibidor de la reabsorción de serotonina y/o norepinefrina - Google Patents
Composición farmacéutica a base de un agonista de receptor adrenérgico beta-3 y un inhibidor de la reabsorción de serotonina y/o norepinefrinaInfo
- Publication number
- ECSP055814A ECSP055814A EC2005005814A ECSP055814A ECSP055814A EC SP055814 A ECSP055814 A EC SP055814A EC 2005005814 A EC2005005814 A EC 2005005814A EC SP055814 A ECSP055814 A EC SP055814A EC SP055814 A ECSP055814 A EC SP055814A
- Authority
- EC
- Ecuador
- Prior art keywords
- beta
- inhibitor
- reabsortion
- norepinefrine
- serotonine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
Esta invención describe una nueva combinación para el tratamiento de trastornos funcionales de la vejiga, que comprende un inhibidor de la reabsorción de serotonina y/o norepinefrina y un agonista de receptor adrenérgico beta-3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02026546A EP1424079A1 (en) | 2002-11-27 | 2002-11-27 | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP055814A true ECSP055814A (es) | 2005-08-11 |
Family
ID=32241298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2005005814A ECSP055814A (es) | 2002-11-27 | 2005-05-23 | Composición farmacéutica a base de un agonista de receptor adrenérgico beta-3 y un inhibidor de la reabsorción de serotonina y/o norepinefrina |
Country Status (22)
Country | Link |
---|---|
US (2) | US20050261328A1 (es) |
EP (4) | EP1424079A1 (es) |
JP (2) | JP2006509751A (es) |
KR (1) | KR20050088295A (es) |
CN (1) | CN1717230A (es) |
AT (1) | ATE399005T1 (es) |
AU (2) | AU2003285312A1 (es) |
BR (1) | BR0316535A (es) |
CA (2) | CA2507266A1 (es) |
CO (1) | CO5580754A2 (es) |
DE (1) | DE50310046D1 (es) |
EA (1) | EA009781B1 (es) |
EC (1) | ECSP055814A (es) |
ES (1) | ES2309371T3 (es) |
HR (1) | HRP20050467A2 (es) |
MX (1) | MXPA05005483A (es) |
NO (1) | NO20053088L (es) |
PL (1) | PL376259A1 (es) |
RS (1) | RS20050392A (es) |
UA (1) | UA81931C2 (es) |
WO (2) | WO2004047830A2 (es) |
ZA (1) | ZA200503282B (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
BRPI0416157A (pt) * | 2003-11-03 | 2007-01-09 | Boehringer Ingelheim Int | composição farmacêutica contendo um agonista de adrenoceptor beta-3 e um antagonista alfa e/ou um inibidor de 5-alfa redutase |
DE10356112A1 (de) * | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff |
EP1804778A1 (de) * | 2004-10-18 | 2007-07-11 | Boehringer Ingelheim International GmbH | Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts |
EP1809591A1 (en) * | 2004-10-26 | 2007-07-25 | Kissei Pharmaceutical Co., Ltd. | Synthesis of phenoxyacetic acid derivatives |
EP1852117A4 (en) * | 2005-02-25 | 2010-10-27 | Astellas Pharma Inc | PHARMACEUTICAL AGENT COMPRISING SOLIFENACIN |
US20060165776A1 (en) * | 2005-08-31 | 2006-07-27 | Ramesh Sesha | Antidepressant oral pharmaceutical compositions |
EP1769792A1 (de) * | 2005-09-30 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co.KG | Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden |
US9440003B2 (en) * | 2005-11-04 | 2016-09-13 | Boston Scientific Scimed, Inc. | Medical devices having particle-containing regions with diamond-like coatings |
FR2895259B1 (fr) * | 2005-12-22 | 2008-02-22 | Urosphere Sas | Methodes de traitement des incontinences urinaires |
EP1974725A4 (en) * | 2006-01-10 | 2012-12-05 | Kissei Pharmaceutical | PREPARATION WITH DELAYED RELEASE AND METHOD OF MANUFACTURING THEREOF |
KR20090005237A (ko) * | 2006-05-22 | 2009-01-12 | 테바 파마슈티컬 인더스트리즈 리미티드 | 둘록세틴 염산염 지연 방출형 제제 |
WO2008020286A2 (en) * | 2006-08-14 | 2008-02-21 | Torrent Pharmaceuticals Limited | Pharmaceutical compositions of duloxetine |
EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
US20080226711A1 (en) * | 2007-03-12 | 2008-09-18 | Torrent Pharmaceuticals Ltd. | Pharmaceutical compositions of duloxetine |
WO2009066181A2 (en) * | 2007-07-09 | 2009-05-28 | Combino Pharm, S.L. | Oral delayed-release duloxentine hydrochloride pellets |
SI2216021T1 (sl) * | 2007-11-02 | 2013-01-31 | Astellas Pharma Inc. | Farmacevtski sestavek za zdravljenje prekomerno aktivnega sečnega mehurja |
TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
ES2376095B1 (es) * | 2008-10-02 | 2013-01-24 | Laboratorios Del Dr. Esteve, S.A. | Pellets entéricos de duloxetina. |
EP2363397A4 (en) * | 2008-11-07 | 2012-07-11 | Dainippon Sumitomo Pharma Co | NEW THERAPEUTIC AGENT USEFUL FOR SYMPTOM OF LOWER URINARY TRACT |
EP2316432A1 (de) * | 2009-10-30 | 2011-05-04 | ratiopharm GmbH | Zusammensetzung enthaltend Fesoterodin und Ballaststoffe |
EP2377525A1 (en) * | 2010-03-26 | 2011-10-19 | Laboratorios del Dr. Esteve S.A. | Duloxetine enteric pellets |
US20120070465A1 (en) | 2010-03-29 | 2012-03-22 | Astellas Pharma Inc. | Pharmaceutical composition for modified release |
TW201208667A (en) * | 2010-08-03 | 2012-03-01 | Altherx Inc | Pharmaceutical combinations |
US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
AR089957A1 (es) * | 2012-02-09 | 2014-10-01 | Altherx Inc | Combinaciones farmaceuticas, combinaciones sinergicas |
SG11201502104YA (en) * | 2012-09-18 | 2015-05-28 | Taris Biomedical Llc | Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium |
PL224543B1 (pl) | 2013-08-21 | 2017-01-31 | Pabianickie Zakłady Farm Polfa Spółka Akcyjna | Dojelitowa tabletka duloksetyny |
EP3226849A4 (en) | 2014-12-03 | 2018-05-09 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
KR20180069865A (ko) | 2015-10-15 | 2018-06-25 | 듀크 유니버시티 | 방광 기능장애를 치료할 수 있는 상태-의존적인 말초 신경제어 |
DK3365321T3 (da) | 2015-10-23 | 2024-01-15 | B3Ar Therapeutics Inc | Solabegron-zwitterion og anvendelser deraf |
US10543174B2 (en) | 2016-04-25 | 2020-01-28 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
US20190307696A1 (en) | 2016-04-25 | 2019-10-10 | Synthon B.V. | Tablets comprising mirabegron and solifenacin |
US10478399B2 (en) | 2017-10-12 | 2019-11-19 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
US12097189B1 (en) | 2024-02-09 | 2024-09-24 | Astellas Pharma Inc. | Pharmaceutical composition for modified release |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4956388A (en) * | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
PH30083A (en) * | 1991-02-25 | 1996-12-27 | Lilly Co Eli | Treatment of lower urinary tract disorders |
IL104567A (en) * | 1992-02-03 | 1997-03-18 | Fujisawa Pharmaceutical Co | Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
US6262115B1 (en) * | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
WO1997015549A1 (fr) * | 1995-10-26 | 1997-05-01 | Tokyo Tanabe Company Limited | COMPOSES DE PHENYLETHANOLAMINE UTILES EN TANT QUE β3 AGONISTES, LEURS PROCEDE ET INTERMEDIAIRES DE PRODUCTION |
US6037362A (en) * | 1996-01-10 | 2000-03-14 | Asahi Kasei Kogyo Kabushiki Kaisha | Tricyclic compounds and drug compositions containing the same |
HUP9902884A3 (en) * | 1996-03-11 | 2000-12-28 | Lilly Co Eli | Use of duloxetine for treating or preventing interstitial cystitis |
EP0924983A4 (en) * | 1996-07-19 | 1999-08-25 | Gunnar Aberg | S (-) - TOLTERODINE FOR THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS |
WO1998007445A1 (fr) * | 1996-08-19 | 1998-02-26 | Kissei Pharmaceutical Co., Ltd. | Remede therapeutique ou preventif contre l'incontinence ou l'elimination urinaire frequente |
WO1998021184A1 (en) * | 1996-11-14 | 1998-05-22 | Pfizer Inc. | Process for substituted pyridines |
WO1998022480A1 (en) * | 1996-11-18 | 1998-05-28 | Smithkline Beecham Plc | Phosphorus containing aryloxy or arylthio propanolamine derivatives |
JPH1112171A (ja) * | 1997-06-19 | 1999-01-19 | Nisshin Flour Milling Co Ltd | 消化器疾患治療薬 |
ID24062A (id) * | 1997-07-25 | 2000-07-06 | Kissei Pharmaceutical | Turunan-turunan asam aminoetilfenoksiasetat dan obat untuk mengurangi nyeri dan membantu penyingkiran dalam litiasis saluran air kencing |
AU9462198A (en) * | 1997-10-17 | 1999-05-10 | Yamanouchi Pharmaceutical Co., Ltd. | Amide derivatives or salts thereof |
DE69818516T2 (de) * | 1997-12-18 | 2004-07-08 | Kissei Pharmaceutical Co., Ltd., Matsumoto | Phenylaminoalkylcarbonsäure-derivate und medizinische zusammensetzungen, die diese enthalten |
US6319920B1 (en) * | 1998-02-27 | 2001-11-20 | Syntex (U.S.A.) Llc | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives |
DE69940484D1 (de) * | 1998-04-06 | 2009-04-09 | Astellas Pharma Inc | Verwendung von beta-3-adrenergen-Rezeptoren Agonisten in der Behandlung von Dysurie |
AU768217C (en) * | 1998-04-14 | 2005-04-21 | Kissei Pharmaceutical Co. Ltd. | 2-methylpropionic acid derivatives and medicinal compositions containing the same |
EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
MY126489A (en) * | 1998-07-08 | 2006-10-31 | Kissei Pharmaceutical | Phenoxyacetic acid derivatives and medicinal compositions containing the same |
PT1039882E (pt) * | 1998-08-27 | 2011-01-03 | Pfizer Health Ab | Formulação terapêutica para administrar tolterodina com libertação controlada |
DE19932651A1 (de) * | 1999-07-13 | 2001-01-18 | Hexal Ag | Transdermales therapeutisches System zur Anwendung von Tolterodin |
EP1078924B1 (en) * | 1999-07-23 | 2004-10-20 | Pfizer Products Inc. | Intermediates and a process for producing beta-adrenergic receptor agonists |
PT1227806E (pt) * | 1999-11-11 | 2005-10-31 | Pfizer Health Ab | Formulacao farmaceutica contendo tolterodina e sua utilizacao |
US6562368B2 (en) * | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers |
SE9904850D0 (sv) * | 1999-12-30 | 1999-12-30 | Pharmacia & Upjohn Ab | Novel process and intermediates |
WO2001054728A1 (en) * | 2000-01-28 | 2001-08-02 | Asahi Kasei Kabushiki Kaisha | NOVEL REMEDIES WITH THE USE OF β3 AGONIST |
CN1660435A (zh) * | 2000-02-24 | 2005-08-31 | 法玛西雅厄普约翰美国公司 | 新的药物联合形式 |
WO2001093683A1 (en) * | 2000-06-07 | 2001-12-13 | Watson Pharmaceuticals, Inc. | Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin |
US6514991B2 (en) * | 2000-07-17 | 2003-02-04 | Wyeth | Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists |
AU2002232470B2 (en) * | 2001-01-02 | 2005-11-03 | Pharmacia & Upjohn Company Llc | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents |
GB0102408D0 (en) * | 2001-01-31 | 2001-03-14 | Glaxo Group Ltd | Chemical compounds |
EP1236723A1 (en) * | 2001-03-01 | 2002-09-04 | Pfizer Products Inc. | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof |
WO2002085871A2 (en) * | 2001-04-04 | 2002-10-31 | Wyeth | Serotonergic agents with long-acting in vivo effects |
WO2003035600A1 (fr) * | 2001-10-19 | 2003-05-01 | Fujisawa Pharmaceutical Co., Ltd. | Procede de production de derive de benzocycloheptene |
BR0206300A (pt) * | 2001-11-05 | 2008-04-08 | Upjohn Co | composição farmacêutica para tratar distúrbio urinário em um mamìfero e uso |
PL372395A1 (en) * | 2002-02-19 | 2005-07-25 | Pharmacia Corporation | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence |
-
2002
- 2002-11-27 EP EP02026546A patent/EP1424079A1/en not_active Withdrawn
-
2003
- 2003-03-11 UA UAA200506227A patent/UA81931C2/uk unknown
- 2003-11-03 JP JP2004554308A patent/JP2006509751A/ja active Pending
- 2003-11-03 CA CA002507266A patent/CA2507266A1/en not_active Abandoned
- 2003-11-03 KR KR1020057009414A patent/KR20050088295A/ko not_active Application Discontinuation
- 2003-11-03 DE DE50310046T patent/DE50310046D1/de not_active Expired - Fee Related
- 2003-11-03 AU AU2003285312A patent/AU2003285312A1/en not_active Abandoned
- 2003-11-03 CN CNA2003801044257A patent/CN1717230A/zh active Pending
- 2003-11-03 ES ES03778298T patent/ES2309371T3/es not_active Expired - Lifetime
- 2003-11-03 EA EA200500776A patent/EA009781B1/ru not_active IP Right Cessation
- 2003-11-03 MX MXPA05005483A patent/MXPA05005483A/es not_active Application Discontinuation
- 2003-11-03 EP EP05027827A patent/EP1640000A3/de not_active Withdrawn
- 2003-11-03 BR BR0316535-3A patent/BR0316535A/pt not_active IP Right Cessation
- 2003-11-03 AT AT03778298T patent/ATE399005T1/de not_active IP Right Cessation
- 2003-11-03 PL PL03376259A patent/PL376259A1/xx unknown
- 2003-11-03 RS RSP-2005/0392A patent/RS20050392A/sr unknown
- 2003-11-03 WO PCT/EP2003/012225 patent/WO2004047830A2/de active IP Right Grant
- 2003-11-03 EP EP03778298A patent/EP1572181B1/de not_active Expired - Lifetime
- 2003-11-05 WO PCT/EP2003/012331 patent/WO2004047838A2/de not_active Application Discontinuation
- 2003-11-05 JP JP2004554318A patent/JP2006509752A/ja active Pending
- 2003-11-05 AU AU2003289854A patent/AU2003289854A1/en not_active Abandoned
- 2003-11-05 EP EP03782183A patent/EP1567149A2/de not_active Withdrawn
- 2003-11-05 CA CA002507343A patent/CA2507343A1/en not_active Abandoned
-
2005
- 2005-04-22 ZA ZA200503282A patent/ZA200503282B/en unknown
- 2005-05-23 EC EC2005005814A patent/ECSP055814A/es unknown
- 2005-05-24 US US11/136,148 patent/US20050261328A1/en not_active Abandoned
- 2005-05-24 US US11/136,165 patent/US20090012161A9/en not_active Abandoned
- 2005-05-25 HR HR20050467A patent/HRP20050467A2/xx not_active Application Discontinuation
- 2005-06-23 NO NO20053088A patent/NO20053088L/no not_active Application Discontinuation
- 2005-06-27 CO CO05062906A patent/CO5580754A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055814A (es) | Composición farmacéutica a base de un agonista de receptor adrenérgico beta-3 y un inhibidor de la reabsorción de serotonina y/o norepinefrina | |
MY134110A (en) | Combinations of reboxetine and neuroleptic agents | |
GEP20084325B (en) | Purine compounds and uses thereof as cannabinoid receptor ligandspurine compounds and uses thereof as cannabinoid receptor ligands | |
MY133238A (en) | Monoamine reuptake inhibitors for treatment for cns disorders | |
HUP0201623A3 (en) | Use of (s,s)reboxetine a selective norepinephrine reuptake inhibitor for the preparation of pharmaceutical compositions treating disorders of the nervous system | |
CR8191A (es) | Derivados 3-amino croman y 2-amino tetralin | |
ZA200509542B (en) | Combination of an NDMA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | |
NZ589951A (en) | 5HT2C receptor modulator compositions and methods of use | |
NO944046L (no) | Ökning av medikamentrespons | |
EP1494673A4 (en) | COMPOUNDS HAVING UNIQUE CB1 RECEPTOR BINDING SELECTIVITY AND METHODS OF PRODUCTION AND USE | |
DE60320865D1 (de) | Zusammensetzung enthaltend einen Tachykininrezeptor Antagonisten und einen Serotonin-Wiederaufnahmehemmer | |
ECSP055885A (es) | Derivados de carbostirilo e inhibidores de la recaptacion de serotonina que sirven para el tratamiento de desordenes en el humor | |
PT1238676E (pt) | Combinacao de um inibidor de reabsorcao de serotonina com um antipsicotico para utilizacao na depressao na patologia obsessiva compulsiva e na psicose | |
SI1641456T1 (sl) | Gaboksadol za zdravljenje depresije in drugih afektivnih motenj | |
BRPI0411665A (pt) | uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina | |
CO6260011A2 (es) | Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del acido 4-hidroxi-4-metil-piperidin-1- carboxilico para el tratamiento del trastorno por estres postraumatico | |
WO2004100939B1 (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
WO2006006152A3 (en) | Treatment of disorders and diseases of the colon | |
IS8388A (is) | Blandan af serótónín endurupptökuhindra og histamín 3 viðtaka mótlyfi, öflugum verka eða hlutaverka | |
RS51669B (en) | NEW DRUG COMBINATIONS AS ANTIDEPRESSIVE | |
BRPI0412268A (pt) | compostos contendo um inibidor seletivo da recaptação de serotonina e antagonista de receptor 5-ht2a | |
EP1260221A3 (en) | Combination treatment for depression and anxiety | |
RU2009101143A (ru) | Лечение психологических состояний с применением антаггонистов m1-мускариновых рецепторов | |
MA30645B1 (fr) | Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine | |
MX2007006045A (es) | Combinacion farmaceutica que comprende inhibidor selectivo de reabsorcion de serotonina y antagonista del receptor de glucocorticoide para tratamiento de depresion. |